{"id":778402,"title":"Bivalent factor H binding protein meningococcal serogroup B: NACI recomendations for use, CCDR 46(2/3) - Canada.ca","sourceCode":"phac","sourceName":"Public Health Agency of Canada","language":"en","captureDate":"2026-03-08","captureTimestamp":"2026-03-08T21:12:48.865000+00:00","jobId":7,"originalUrl":"https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-2-3-february-6-2020/article-3-naci-bivalent-factor-h-binding-protein-meningococcal-serogroup-b.html","snippet":"NACI Summary of MenB-fHBP Download this article as a PDF Published by: The Public Health Agency of Canada Issue: Volume 46–2/3: Public Health Network Date published: February 6, 2020 ISSN: 1481-8531 Subscribe to CCDR Submit your manuscript Information for authors About CCDR…","rawSnapshotUrl":"/api/snapshots/raw/778402","browseUrl":"https://replay.healtharchive.ca/job-7/20260308211248/https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-2-3-february-6-2020/article-3-naci-bivalent-factor-h-binding-protein-meningococcal-serogroup-b.html#ha_snapshot=778402","mimeType":"text/html","statusCode":200,"captureBackend":"playwright_warc","captureFidelity":"fallback"}